Enliven Therapeutics (ELVN) Competitors $17.05 -0.14 (-0.81%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$17.07 +0.02 (+0.09%) As of 04/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN vs. RYTM, PTCT, OGN, ZLAB, ACLX, RNA, RARE, AKRO, MOR, and SWTXShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Organon & Co. (OGN), Zai Lab (ZLAB), Arcellx (ACLX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), MorphoSys (MOR), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. Rhythm Pharmaceuticals PTC Therapeutics Organon & Co. Zai Lab Arcellx Avidity Biosciences Ultragenyx Pharmaceutical Akero Therapeutics MorphoSys SpringWorks Therapeutics Enliven Therapeutics (NASDAQ:ELVN) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Which has preferable earnings & valuation, ELVN or RYTM? Enliven Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$71.58M-$1.89-9.02Rhythm Pharmaceuticals$130.13M30.17-$184.68M-$4.35-14.27 Is ELVN or RYTM more profitable? Enliven Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Enliven Therapeutics' return on equity of -29.46% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -29.46% -27.33% Rhythm Pharmaceuticals -230.07%-367.36%-77.47% Do analysts prefer ELVN or RYTM? Enliven Therapeutics presently has a consensus price target of $40.33, suggesting a potential upside of 136.56%. Rhythm Pharmaceuticals has a consensus price target of $74.92, suggesting a potential upside of 20.67%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Enliven Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in ELVN or RYTM? 95.1% of Enliven Therapeutics shares are held by institutional investors. 29.2% of Enliven Therapeutics shares are held by insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, ELVN or RYTM? Enliven Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500. Does the media prefer ELVN or RYTM? In the previous week, Rhythm Pharmaceuticals had 18 more articles in the media than Enliven Therapeutics. MarketBeat recorded 26 mentions for Rhythm Pharmaceuticals and 8 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.74 beat Rhythm Pharmaceuticals' score of 0.61 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Rhythm Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in ELVN or RYTM? Rhythm Pharmaceuticals received 298 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 68.06% of users gave Rhythm Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEnliven TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesRhythm PharmaceuticalsOutperform Votes30968.06% Underperform Votes14531.94% SummaryEnliven Therapeutics beats Rhythm Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Remove Ads Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$835.52M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-8.976.7921.7317.82Price / SalesN/A225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book2.865.866.464.00Net Income-$71.58M$141.86M$3.20B$247.23M7 Day Performance3.21%4.50%2.86%1.45%1 Month Performance-17.79%-12.65%-8.55%-6.24%1 Year Performance-8.77%-11.06%10.47%0.60% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics2.5632 of 5 stars$17.05-0.8%$40.33+136.6%-14.5%$835.52MN/A-8.9750News CoverageRYTMRhythm Pharmaceuticals3.7043 of 5 stars$54.96+17.1%$73.31+33.4%+54.9%$3.47B$130.13M-12.69140High Trading VolumePTCTPTC Therapeutics3.884 of 5 stars$42.82-1.0%$63.77+48.9%+82.8%$3.38B$806.78M-7.211,410Short Interest ↑Positive NewsOGNOrganon & Co.4.798 of 5 stars$12.54-3.9%$20.80+65.9%-37.5%$3.23B$6.40B3.7610,000Short Interest ↓ZLABZai Lab2.4929 of 5 stars$28.81-9.3%$47.37+64.4%+113.9%$3.16B$398.99M-10.401,950News CoverageGap DownHigh Trading VolumeACLXArcellx1.9881 of 5 stars$56.65-3.3%$110.67+95.4%+7.8%$3.11B$107.94M-79.7980Positive NewsHigh Trading VolumeRNAAvidity Biosciences2.2721 of 5 stars$25.48-4.1%$66.69+161.7%+11.6%$3.06B$10.90M-8.85190RAREUltragenyx Pharmaceutical4.5522 of 5 stars$32.14-0.9%$92.79+188.7%-17.6%$3.02B$560.23M-5.071,310Positive NewsGap DownAKROAkero Therapeutics4.3059 of 5 stars$35.97-2.1%$76.29+112.1%+75.3%$2.86BN/A-9.5930Gap DownHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics2.0634 of 5 stars$36.99-5.4%$73.20+97.9%-11.6%$2.77B$191.59M-10.63230Positive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors PTC Therapeutics Competitors Organon & Co. Competitors Zai Lab Competitors Arcellx Competitors Avidity Biosciences Competitors Ultragenyx Pharmaceutical Competitors Akero Therapeutics Competitors MorphoSys Competitors SpringWorks Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELVN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELVN Stock Free ELVN Stock Alerts